A Case Report of Severe Hypovolemic Hyponatremia Secondary to Angiotensin Receptor Blocker- thiazide Diuretic Usage
Mohammed Ziauddin *
Apollo Hospitals, Jubilee Hills, Hyderabad, India.
Mohammed Zabeer Uddin
Sri Venkateshwara College of Pharmacy, India.
Ummay Mariya
Anwar-ul-uloom College of Pharmacy, India.
Tarannum Fatima
Anwar-ul-uloom College of Pharmacy, India.
*Author to whom correspondence should be addressed.
Abstract
Key Clinical Message: Telmisartan-hydrochlorthiazide is a US FDA and CDSCO approved oral Fixed Dose combination of ARB & Diuretic for treating hypertension as second line therapy. Telmisartan is an ARBs prevent angiotensin II acting on AT1 receptors and are similar to ACEIs, but have no effect on bradykinin and do not cause cough or bradykinin-related anaphylaxis. We describe a case report of 59-Year-old female who developed severe hyponatremia following the recent administration of Telmisartan-hydrochlorthiazide Combination. Clinical and laboratory evaluations suggest severe Hypovolemic Hyponatremia, likely secondary to Angiotensin receptor blocker-thiazide diuretic. The potential side effects of this Fixed Dose Combination medication requires regular monitoring, patient education.
Keywords: Hyponatremia, Telmisartan-hydrochlorthiazide, ARB-Angiotensin Receptor Blocker